Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

Most biopharma brands have more approved content than ever before. Yet HCP and patient engagement haven’t kept pace. | Omnichannel isn’t a content problem. It’s an access problem. See how compliant AI ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS Secretary Robert F. Kennedy Jr. is continuing to reshape the Centers for Disease Control ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...

Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to eliminate 114 positions ...

Charles River Laboratories has backed an American Heart Association (AHA) campaign, joining forces with the nonprofit on ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...